In this phase IIb parallel cohort study, patients with BCG-unresponsive carcinoma in situ (CIS) with/without papillary disease received TAR-200 monotherapy (Cohort 2 [C2]), TAR-200 plus cetrelimab (C1 ...
Building on the foundational concepts introduced in a prior webinar, this follow-up session will focus on how multimodal real-world clinical data can be used to define and investigate research cohorts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback